BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, April 17-22 in San Diego.

Rhea-AI Summary

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, April 17-22 in San Diego.

BBOT will present an oral session on BBO-10203 inhibiting PI3Kα/AKT via non-canonical RAS signaling on April 21, and a poster on BBO-11818 KRAS inhibitors on April 22.

Argus Mar 19 session

+1.91% close to close Open Argus

Details

News Market Reaction – BBOT

In the Mar 19 session, BBOT gained 1.91%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights upcoming AACR 2026 presentations for BBO-10203 and BBO-11818, underscor...

Analysis

This announcement highlights upcoming AACR 2026 presentations for BBO-10203 and BBO-11818, underscoring BBOT’s focus on RAS-pathway and PI3Kα-driven cancers. It follows recent data disclosures, including preclinical work and early clinical signals. With shares trading below the 200-day MA $11.36 yet only 8.97% above the 52-week low, investors may watch how detailed AACR data compare with prior KRAS and PI3Kα results and how they support the broader development strategy.

Key Figures

AACR meeting dates: April 17–22, 2026 Oral session time: April 21, 2:30–4:30 p.m. PT Oral abstract number: 6780 +3 more

AACR meeting dates

April 17–22, 2026

AACR Annual Meeting 2026 in San Diego

Oral session time

April 21, 2:30–4:30 p.m. PT

Oral presentation for BBO-10203

Oral abstract number

6780

BBO-10203 oral AACR abstract

Poster session time

April 22, 9:00 a.m.–12:00 p.m. PT

Poster presentation for BBO-11818

Poster board number

24

AACR poster board for BBO-11818

Poster number

7104

AACR poster number for BBO-11818

Historical Context

5 past events · Latest: Mar 06

5 events

1. Mar 06

   Preclinical publication

   24h Move

   +5.4%

   Cancer Discovery paper on BBO‑11818 panKRAS inhibitor with strong preclinical data.

2. Mar 05

   Earnings and update

   24h Move

   +5.4%

   Q4 and 2025 results plus cash runway and clinical progress across three programs.

3. Feb 12

   Conference participation

   24h Move

   -1.5%

   Announcement of participation in upcoming investor healthcare conferences.

4. Feb 11

   Inducement grants

   24h Move

   -5.2%

   Stock-option inducement grants to new employees under 2025 Inducement Plan.

5. Jan 13

   Inducement grants

   24h Move

   +4.6%

   Inducement stock options for a new hire with long-term vesting schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pi3kα, akt, her2+, non-covalent, +2 more

6 terms

pi3kα medical

"The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models"

PI3Kα is a specific form of an enzyme that acts like a cellular switchboard controlling signals for cell growth, survival and movement; think of it as a traffic controller that helps decide when cells divide or stay alive. It matters to investors because drugs that block or modify this enzyme can slow tumor growth or cause side effects, so clinical trial results, approvals or safety concerns around PI3Kα-targeting therapies can significantly affect company value.

akt medical

"BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical signaling"

AKT is a family of enzymes inside cells that act like circuit breakers for growth, survival and energy use, turning biological pathways on or off. It matters to investors because drugs or diagnostics that target AKT can change the course of development for treatments in areas such as cancer and metabolic disease, affecting clinical trial results, regulatory chances and a company’s valuation much like a key part failing or working in an industrial system.

her2+ medical

"inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling"

HER2+ means a tumor has abnormally high levels or extra copies of the HER2 protein, a growth receptor on cell surfaces; imagine cells with extra antennae picking up signals that make them divide faster. For investors, HER2+ status defines a clear market for targeted drugs and diagnostic tests, shaping clinical trial needs, regulatory approvals, treatment adoption, and therefore potential revenue and valuation for companies involved in therapies or tests.

non-covalent medical

"an orally bioavailable, highly potent and selective non-covalent pan-KRAS (ON) and (OFF) inhibitor"

Non-covalent describes a type of interaction where molecules stick together through weak, reversible forces rather than forming permanent chemical bonds. For investors, non-covalent binding in drugs or diagnostics signals treatments that are often adjustable, shorter-acting, and potentially easier to reverse or fine-tune than covalent counterparts, which affects safety profiles, dosing strategies, patenting approaches and how a product may perform in the market.

pan-kras medical

"selective non-covalent pan-KRAS (ON) and (OFF) inhibitor with robust anti-tumor activity"

Pan-KRAS describes a drug or therapeutic approach designed to work against many different mutations of the KRAS gene rather than a single specific variant. For investors, a pan-KRAS treatment is important because it can address a larger group of patients—like a universal key that fits many locks—potentially increasing the market opportunity and clinical value, while also carrying development and regulatory risks tied to demonstrating safety and broad effectiveness.

anti-tumor activity medical

"inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models"

Anti-tumor activity describes evidence that a drug or treatment can reduce tumor size, slow or stop tumor growth, or prevent new tumors from forming in lab, animal, or human studies. For investors this signals the treatment’s potential to succeed in clinical development and reach the market; like early road-test results for a new car, stronger anti-tumor activity generally raises the odds of regulatory approval, commercial value and return on investment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website here.

Details on the presentations are as follows:

• Title: The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockade
• Session Category: Experimental and Molecular Therapeutics
• Session Title: Targeted Protein Degradation and Non-cannonical Oncogenic Signaling
• Session Type: Oral Presentation
• Session Date/Time: Tuesday, April 21, 2:30 p.m. – 4:30 p.m. PT
• Location: Upper Level Ballroom 6DE
• Abstract Number: 6780 
• Presenter: James Stice, PhD, Director, BBOT
  
  

• Title: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS (ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
• Session Category: Experimental and Molecular Therapeutics
• Session Title: Novel Antitumor Agents 3
• Session Type: Poster Presentation
• Session Date/Time: Wednesday, April 22, 9:00 a.m. – 12:00 p.m. PT
• Location: Poster Section 13
• Poster Board Number: 24
• Poster Number: 7104
• Presenter: Carlos Stahlhut, PhD, Associate Director, BBOT
  
  

About BBO-11818
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS-mutant preclinical models, including KRAS^G12D and KRAS^G12V. BBO-11818 potently suppresses MAPK signaling and inhibits cell proliferation in KRAS-mutant cell lines and mouse models. BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors.

About BBO-10203
BBO-10203 is a first-in-class small molecule which breaks the protein-protein interaction between RAS and PI3Kα and inhibits RAS-mediated activation of the PI3Kα pathway. It selectively disrupts oncogenic RAS-PI3Kα signaling while sparing insulin-mediated glucose uptake, potentially maintaining efficacy with reduced risk of hyperglycemia or hyperinsulinemia. BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS-mutant colorectal cancer, and KRAS-mutant non-small cell lung cancer.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong
BBOT
Heather.Armstrong@bbotx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will BBOT present BBO-10203 at AACR 2026 (BBOT)?

BBOT will present BBO-10203 in an oral session on April 21, 2026, at 2:30–4:30 p.m. PT. According to the company, the talk is in the Experimental and Molecular Therapeutics category in Upper Level Ballroom 6DE, abstract number 6780.

What is BBOT presenting about BBO-11818 at AACR 2026 (BBOT)?

BBOT will present a poster on BBO-11818 on April 22, 2026, from 9:00 a.m.–12:00 p.m. PT. According to the company, the poster covers a non-covalent pan-KRAS inhibitor with preclinical anti-tumor activity, Poster 7104 in Poster Section 13.

How can investors access BBOT abstracts for AACR 2026 (BBOT)?

Investors can view the released abstracts on the AACR website linked by the company. According to the company, the abstracts were released March 18, 2026, and include session details, presenters, and abstract numbers for reference.

Who are the BBOT presenters at AACR 2026 and their roles (BBOT)?

BBOT presenters include James Stice, PhD, and Carlos Stahlhut, PhD. According to the company, James Stice will present the oral on BBO-10203 and Carlos Stahlhut will present the BBO-11818 poster.

Does BBOT specify clinical data timing or results at AACR 2026 (BBOT)?

The announcement lists presentation titles and session details but does not provide clinical readout timing or detailed results. According to the company, the abstracts on the AACR site contain the scientific content to be presented at the meeting.